Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters
- Authors:
- Kai Gao
- Xiaorong Li
- Gui Hu
- Kaiyan Yang
- Buning Tian
- Yi Zhang
View Affiliations
Affiliations: Department of General Surgery, The Third Affiliated Hospital of Central South University, Central South University, Changsha, Hunan 410013, P.R. China
- Published online on: August 6, 2012 https://doi.org/10.3892/ol.2012.854
-
Pages:
988-992
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Deleted in liver cancer 2 (DLC2) has been identified as a tumor suppressor gene. DLC2 is closely related to deleted in liver cancer 1 (DLC1) and is located at chromosome 13q12.3. The expression of DLC2 mRNA has been found in a wide range of cancers, including colorectal cancer (CRC). However, there are no available data on the expression status of DLC2 in Chinese patients with CRC and its correlation with clinicopathological parameters. The aim of this study was to investigate the expression levels of DLC2 mRNA and protein in Chinese patients with CRC and the correlation between DLC2 expression and clinicopathological parameters. To this end, real-time PCR, western blotting and immunohistochemistry were employed to detect DLC2 mRNA and protein expression in CRC and pericarcinomatous intestinal tissue (PCIT) specimens, which were obtained from 102 Chinese CRC patients who underwent surgical resection between October 2010 and February 2012. We also analyzed the correlations between DLC2 expression and the clinicopathological parameters of CRC patients. Our results showed that CRC tissues had significantly lower levels of DLC2 mRNA compared with PCITs (P<0.05); however, the protein expression levels were not significantly different between CRCs and PCITs. The expression levels of DLC2 mRNA and protein were significantly correlated with lymph node metastasis and tumor TNM stage. Additionally, DLC2 mRNA expression levels were also correlated with tumor histopathological degree (P<0.05). Collectively, our results suggest that the downregulated expression of DLC2 participates in CRC carcinogenesis, invasion and lymph node metastasis. Furthermore, our results imply that DLC2 is be a potential prognostic marker for CRC patients.
View References
1.
|
A JemalF BrayMM CenterJ FerlayE WardD
FormanGlobal cancer statisticsCA Cancer J
Clin616990201110.3322/caac.20107
|
2.
|
HJ WilkeE Van CutsemCurrent treatments and
future perspectives in colorectal and gastric cancerAnn
Oncol14Suppl 2ii49ii55200310.1093/annonc/mdg73012810459
|
3.
|
YP ChingCM WongSF ChanDeleted in liver
cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor
function and is underexpressed in hepatocellular carcinomaJ Biol
Chem2781082410830200310.1074/jbc.M20831020012531887
|
4.
|
TH LeungYP ChingJW YamDeleted in liver
cancer 2 (DLC2) suppresses cell transformation by means of
inhibition of RhoA activityProc Natl Acad Sci
USA1021520715212200510.1073/pnas.050450110216217026
|
5.
|
DC NgSF ChanKH KokMitochondrial targeting
of growth suppressor protein DLC2 through the START domainFEBS
Lett580191198200610.1016/j.febslet.2005.11.07316364308
|
6.
|
L XiaorongW WeiQ LiyuanY
KaiyanUnderexpression of deleted in liver cancer 2 (DLC2) is
associated with overexpression of RhoA and poor prognosis in
hepatocellular carcinomaBMC
Cancer8205200810.1186/1471-2407-8-20518651974
|
7.
|
V UllmannovaNC PopescuExpression profile
of the tumor suppressor genes DLC-1 and DLC-2 in solid tumorsInt J
Oncol2911271132200617016643
|
8.
|
TH LeungJW YamLK ChanYP ChingIO NgDeleted
in liver cancer 2 suppresses cell growth via the regulation of the
Raf-1-ERK1/2-p70S6K signalling pathwayLiver
Int3013151323201010.1111/j.1478-3231.2010.02307.x20629949
|
9.
|
Y LinNT ChenYP ShihYC LiaoL XueSH LoDLC2
modulates angiogenic responses in vascular endothelial cells by
regulating cell attachment and
migrationOncogene2930103016201010.1038/onc.2010.5420208559
|
10.
|
AB JaffeA HallRho GTPases in
transformation and metastasisAdv Cancer
Res845780200210.1016/S0065-230X(02)84003-911883532
|
11.
|
T KamaiK AraiT TsujiiM HondaK
YoshidaOverexpression of RhoA mRNA is associated with advanced
stage in testicular germ cell tumourBJU
Int87227231200110.1046/j.1464-410x.2001.02030.x11167647
|
12.
|
G FritzI JustB KainaRho GTPases are
over-expressed in human tumorsInt J
Cancer81682687199910.1002/(SICI)1097-0215(19990531)81:5%3C682::AID-IJC2%3E3.0.CO;2-B10328216
|
13.
|
T KamaiT TsujiiK AraiSignificant
association of Rho/ROCK pathway with invasion and metastasis of
bladder cancerClin Cancer Res926322641200312855641
|
14.
|
Y TakamiM HigashiS KumagaiThe activity of
RhoA is correlated with lymph node metastasis in human colorectal
cancerDig Dis Sci53467473200810.1007/s10620-007-9887-017597401
|
15.
|
Y LuoJ CuiC ChenClinical outcomes after
surgical resection of colorectal cancer in 1,294
patientsHepatogastroenterology5913981402201122115801
|
16.
|
S GillCL LoprinziDJ SargentPooled analysis
of fluorouracil-based adjuvant therapy for stage II and III colon
cancer: who benefits and by how much?J Clin
Oncol2217971806200410.1200/JCO.2004.09.05915067028
|